Apogee Therapeutics recently completed a follow-on equity offering of approximately US$403,000,000, issuing 5,750,000 common shares at US$70.00 each after reporting positive 52-week Phase 2 APEX data ...

Standard Chartered’s central fair value estimate is now set at £19.25 versus £18.94 previously, with fresh analyst price targets clustering between £18.65 and £22.00 around that mark. Taken together, ...

Don't miss the subtle yet significant changes to Volvo's flagship SUV. Find out what's new and why it matters in our exclusive review.